CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes

Blood Cancer J. 2021 Mar 11;11(3):54. doi: 10.1038/s41408-021-00449-9.

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
³ Faculte de Medecine, Universite Paris-Saclay, 94270, Le Kremlin-Bicetre, France.
⁴ Department of Hematology and INSERM U1287, Gustave Roussy Cancer Center, 94805, Villejuif, France.
⁵ Division of Hematology, Mayo Clinic, Rochester, MN, USA. patnaik.mrinal@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Cell Proliferation
Female
Humans
Leukemia, Myelomonocytic, Chronic / diagnosis
Leukemia, Myelomonocytic, Chronic / genetics*
Male
Middle Aged
Mutation
Prognosis
Receptors, Colony-Stimulating Factor / genetics*
Repressor Proteins / genetics*

Substances

ASXL1 protein, human
CSF3R protein, human
Receptors, Colony-Stimulating Factor
Repressor Proteins